Dasatinib (Dasatinib) Patent Expiration, LOE Window & CMS Spending

Dasatinib (Dasatinib) by Apotex: Multi-Source Generic Molecule, 10 AB generics, $70.1M 2024 CMS Part D & Medicaid spend, and $13,894 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorApotex
FDA Application & PathwayReconciled (ANDA)
Exclusivity / Cliff HorizonMulti-Source Generic Molecule
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors10
2024 CMS Total Public Spend$70.1M
2024 Medicare Part D Spend$50.2M
2024 Medicaid Spend$19.9M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($13,894 intro WAC)